9,000,000 Shares Veraz Networks, Inc. Common Stock, par value $0.001 per share UNDERWRITING AGREEMENT
Exhibit 1.1
9,000,000 Shares
Common Stock, par value $0.001 per share
[DATE]
Credit Suisse Securities (USA) LLC, and
Xxxxxx Brothers Inc.
As Representatives of the Underwriters,
Xxxxxx Brothers Inc.
As Representatives of the Underwriters,
Credit Suisse Securities (USA) LLC,
Xxxxxx Brothers Inc.
Xxxxxxxx & Company, Inc.
Xxxxxxx Xxxxx & Associates, Inc.
Xxxxxx Brothers Inc.
Xxxxxxxx & Company, Inc.
Xxxxxxx Xxxxx & Associates, Inc.
c/o | Credit Suisse Securities (USA) LLC, Eleven Xxxxxxx Xxxxxx, Xxx Xxxx, XX 00000-0000 |
And | Xxxxxx Brothers Inc. 000 0xx Xxxxxx Xxx Xxxx, XX 00000 |
Dear Sirs:
1. Introductory. Veraz Networks, Inc., a Delaware corporation (“Company”), proposes to issue
and sell [•] shares of its Common Stock, par value $0.001 per share (“Securities”) and ECI
Telecom, Ltd. (“Selling Stockholder”) proposes to sell [•] outstanding shares of the
Securities (collectively, such [•] shares of Securities being hereinafter referred to as the
“Firm Securities”). The Company also proposes to sell to the Underwriters (as defined below), for
whom Credit Suisse Securities (USA), LLC and Xxxxxx Brothers Inc. are acting as representatives
(the “Representatives”), at the option of the Underwriters, an aggregate of not more than [•]
additional shares of its Securities. and the Selling Stockholder also proposes to sell to the
Underwriters, at the option of the Underwriters, not more than [•] additional outstanding
shares of the Company’s Securities, as set forth below (collectively, such [•] additional
shares being hereinafter referred to as the “Optional Securities”). The Firm Securities and the
Optional Securities are herein collectively called the “Offered Securities”. The Company and the
Selling Stockholder hereby agree with the several Underwriters named in Schedule A
(“Underwriters”) as follows:
2. Representations and Warranties of the Company and the Selling Stockholder. (a) The Company
represents and warrants to, and agrees with, the several Underwriters that:
(i) A registration statement (No. 333-138121) relating to the Offered Securities, including a
form of prospectus, has been filed with the Securities and Exchange Commission (“Commission”) and
either (A) has been declared effective under the Securities Act of 1933 (“Act”) and is not proposed
to be amended or (B) is proposed to be amended by amendment or post-effective amendment. If such
registration statement (the “initial registration statement”) has been declared effective, either
(A) an additional registration statement (the “additional registration statement”) relating to the
Offered Securities may have been filed with the Commission pursuant to Rule 462(b) (“Rule 462(b)”)
under the Act and, if so filed, has become effective upon filing pursuant to such Rule and the
Offered Securities all have been duly registered under the Act pursuant to the initial registration
statement and, if applicable, the
additional registration statement or (B) such an additional registration statement is proposed
to be filed with the Commission pursuant to Rule 462(b) and will become effective upon filing
pursuant to such Rule and upon such filing the Offered Securities will all have been duly
registered under the Act pursuant to the initial registration statement and such additional
registration statement. If the Company does not propose to amend the initial registration
statement or if an additional registration statement has been filed and the Company does not
propose to amend it, and if any post-effective amendment to either such registration statement has
been filed with the Commission prior to the execution and delivery of this Agreement, the most
recent amendment (if any) to each such registration statement has been declared effective by the
Commission or has become effective upon filing pursuant to Rule 462(c) (“Rule 462(c)”) under the
Act or, in the case of the additional registration statement, Rule 462(b). For purposes of this
Agreement, “Effective Time” with respect to the initial registration statement or, if filed prior
to the execution and delivery of this Agreement, the additional registration statement means (A) if
the Company has advised the Representatives that it does not propose to amend such registration
statement, the date and time as of which such registration statement, or the most recent
post-effective amendment thereto (if any) filed prior to the execution and delivery of this
Agreement, was declared effective by the Commission or has become effective upon filing pursuant to
Rule 462(c), or (B) if the Company has advised the Representatives that it proposes to file an
amendment or post-effective amendment to such registration statement, the date and time as of which
such registration statement, as amended by such amendment or post-effective amendment, as the case
may be, is declared effective by the Commission. If an additional registration statement has not
been filed prior to the execution and delivery of this Agreement but the Company has advised the
Representatives that it proposes to file one, “Effective Time” with respect to such additional
registration statement means the date and time as of which such registration statement is filed and
becomes effective pursuant to Rule 462(b). “Effective Date” with respect to the initial
registration statement or the additional registration statement (if any) means the date of the
Effective Time thereof. The initial registration statement, as amended at its Effective Time,
including all information contained in the additional registration statement (if any) and deemed to
be a part of the initial registration statement as of the Effective Time of the additional
registration statement pursuant to the General Instructions of the Form on which it is filed and
including all information (if any) deemed to be a part of the initial registration statement as of
its Effective Time pursuant to Rule 430A(b) under the Act (“Rule 430A(b)”), is hereinafter referred
to as the “Initial Registration Statement”. The additional registration statement, as amended at
its Effective Time, including the contents of the initial registration statement incorporated by
reference therein and including all information (if any) deemed to be a part of the additional
registration statement as of its Effective Time pursuant to Rule 430A(b), is hereinafter referred
to as the “Additional Registration Statement”. The Initial Registration Statement and the
Additional Registration are hereinafter referred to collectively as the “Registration Statements”
and individually as a “Registration Statement”. “Registration Statement” without reference to a
time means the Registration Statement as of its Effective Time. “Registration Statement”
as of any
time means the initial registration statement and any additional registration statement in the form
then filed with the Commission, including any amendment thereto and any prospectus deemed or
retroactively deemed to be a part thereof that has not been superseded or modified. For purposes of
the previous sentence, information contained in the a form of prospectus or prospectus supplement
that is deemed retroactively to be a part of the Registration Statement pursuant to Rule 430A shall
be considered to be included in the Registration Statement as of the time specified in Rule 430A.
“Statutory Prospectus” as of any time means the prospectus included in the Registration Statement
immediately prior to that time, including any prospectus deemed to be a part thereof that has not
been superseded or modified. For purposes of the preceding sentence, information contained in a
form of prospectus that is deemed retroactively to be a part of the Registration Statement pursuant
to Rule 430A shall be considered to be included in the Statutory Prospectus as of the actual time
that form of prospectus is filed with the Commission pursuant to Rule 424(b) (“Rule 424(b)”) under
the Act. “Prospectus” means the Statutory Prospectus that discloses the public offering price and
other final terms of the Offered Securities and otherwise satisfies Section 10(a) of the Act.
“Issuer Free Writing Prospectus” means any “issuer free writing prospectus”, as defined in Rule
433, relating to the Offered Securities in the form filed or required to be filed with the
Commission or, if not required to be filed, in the form retained in the Company’s records pursuant
to Rule 433(g). “General Use Issuer Free Writing Prospectus “ means any Issuer Free Writing
Prospectus that is intended for general distribution to prospective investors, as evidenced by its
being specified in a schedule to this Agreement. “Limited Use Issuer Free Writing
-2-
Prospectus” means any Issuer Free Writing Prospectus that is not a General Use Issuer Free
Writing Prospectus. “Applicable Time” means [•]:00 [a/p]m (Eastern time) on [•].
(ii) If the Effective Time of the Initial Registration Statement is prior to the execution and
delivery of this Agreement: (A) on the Effective Date of the Initial Registration Statement, the
Initial Registration Statement conformed in all respects to the requirements of the Act and the
rules and regulations of the Commission (“Rules and Regulations”) and did not include any untrue
statement of a material fact or omit to state any material fact required to be stated therein or
necessary to make the statements therein not misleading, (B) on the Effective Date of the
Additional Registration Statement (if any), each Registration Statement conformed or will conform,
in all respects to the requirements of the Act and the Rules and Regulations and did not include,
or will not include, any untrue statement of a material fact and did not omit, or will not omit, to
state any material fact required to be stated therein or necessary to make the statements therein
not misleading, and (C) on the date of this Agreement, the Initial Registration Statement and, if
the Effective Time of the Additional Registration Statement is prior to the execution and delivery
of this Agreement, the Additional Registration Statement each conforms, and at the time of filing
of the Prospectus pursuant to Rule 424(b) or (if no such filing is required) at the Effective Date
of the Additional Registration Statement in which the Prospectus is included, each Registration
Statement and the Prospectus will conform, in all respects to the requirements of the Act and the
Rules and Regulations, and neither of such documents includes, or will include, any untrue
statement of a material fact or omits, or will omit, to state any material fact required to be
stated therein or necessary to make the statements therein not misleading. If the Effective Time
of the Initial Registration Statement is subsequent to the execution and delivery of this
Agreement: on the Effective Date of the Initial Registration Statement, the Initial Registration
Statement and the Prospectus will conform in all respects to the requirements of the Act and the
Rules and Regulations, neither of such documents will include any untrue statement of a material
fact or will omit to state any material fact required to be stated therein or necessary to make the
statements therein not misleading, and no Additional Registration Statement has been or will be
filed. The two preceding sentences do not apply to statements in or omissions from a Registration
Statement or the Prospectus based upon written information furnished to the Company by any
Underwriter through the Representatives specifically for use therein, it being understood and
agreed that the only such information is that described as such in Section 8(d) hereof.
(iii) (A) At the time of filing the Registration Statement and (B) at the date of this
Agreement, the Company was not and is not an “ineligible issuer” as defined in Rule 405.
(iv) As of the Applicable Time, neither (A) the General Use Issuer Free Writing Prospectus(es)
issued at or prior to the Applicable Time and the Statutory Prospectus, all considered together
(collectively, the “General Disclosure Package”), nor (B) any individual Limited Use Issuer Free
Writing Prospectus, when considered together with the General Disclosure Package, included any
untrue statement of a material fact or omitted to state any material fact necessary in order to
make the statements therein, in the light of the circumstances under which they were made, not
misleading. The preceding sentence does not apply to statements in or omissions from any prospectus
included in the Registration Statement or any Issuer Free Writing Prospectus in reliance upon and
in conformity with written information furnished to the Company by any Underwriter through the
Representatives specifically for use therein, it being understood and agreed that the only such
information furnished by any Underwriter consists of the information described as such in Section
8(d) hereof.
(v) Each Issuer Free Writing Prospectus, as of its issue date and at all subsequent times
through the completion of the public offer and sale of the Offered Securities or until any earlier
date that the Company notified or notifies the Representatives as described in the next sentence,
did not, does not and will not include any information that conflicted, conflicts or will conflict
with the information then contained in the Registration Statement. If at any time following
issuance of an Issuer Free Writing Prospectus there occurred or occurs an event or development as a
result of which such Issuer Free Writing Prospectus conflicted or would conflict with the
information then contained in the Registration Statement or included or would include an untrue
statement of a material fact or omitted or
-3-
would omit to state a material fact necessary in order to make the statements therein, in the
light of the circumstances prevailing at that subsequent time, not misleading, (A) the Company has
promptly notified or will promptly notify the Representatives and (B) the Company has promptly
amended or will promptly amend or supplement such Issuer Free Writing Prospectus to eliminate or
correct such conflict, untrue statement or omission. The foregoing two sentences do not apply to
statements in or omissions from any Issuer Free Writing Prospectus in reliance upon and in
conformity with written information furnished to the Company by any Underwriter through the
Representatives specifically for use therein, it being understood and agreed that the only such
information furnished by any Underwriter consists of the information described as such in Section
8(d) hereof.
(vi) The Company has been duly incorporated and is an existing corporation in good standing
under the laws of the State of Delaware, with corporate power and authority to own its properties
and conduct its business as described in the General Disclosure Package; and the Company is duly
qualified to do business as a foreign corporation in good standing in all other jurisdictions in
which its ownership or lease of property or the conduct of its business requires such
qualification.
(vii) Each subsidiary of the Company has been duly incorporated or formed and is in good
standing under the laws of the jurisdiction of its formation, with corporate or similar power and
authority to own its properties and conduct its business as described in the General Disclosure
Package; and each subsidiary of the Company is duly qualified to do business and in good standing
in all other jurisdictions in which its ownership or lease of property or the conduct of its
business requires such qualification and where the failure to be so qualified individually or in
the aggregate would result in a material adverse effect, or any development reasonably likely to
result in a prospective material adverse effect, on the condition (financial or other), business,
properties, or results of operation of the Company and its subsidiaries taken as a whole
(“Material Adverse Effect”); all of the issued and outstanding capital stock of each subsidiary of
the Company has been duly authorized and validly issued and is fully paid and nonassessable; and
the capital stock of each subsidiary owned by the Company, directly or through subsidiaries, is
owned free from liens, encumbrances and defects.
(viii) The entities listed on Schedule B hereto are the only subsidiaries of the Company.
(ix) The Company has an authorized capitalization as set forth in the Prospectus and all of
the issued shares of capital stock of the Company have been duly and validly authorized and issued
and are fully paid and non-assessable and conform to the description that is contained in the
Prospectus; and all of the issued shares of capital stock of each subsidiary of the Company have
been duly and validly authorized and issued, are fully paid and non-assessable and are owned
directly or indirectly by the Company, free and clear of all liens, encumbrances, equities or
claims.
(x) The Offered Securities to be sold by the Company have been duly authorized, and, when
issued and delivered to the Underwriters against payment therefor in accordance with this Agreement
on each Closing Date (as defined below), such Offered Securities will have been, validly issued,
fully paid and nonassessable and will conform in all material respects to the description thereof
contained in the Prospectus and the General Disclosure Package.
(xi) The Offered Securities to be sold by the Selling Stockholders that are outstanding as of
the date hereof and all other outstanding shares of capital stock of the Company have been duly
authorized and validly issued and are fully paid and nonassessable and conform in all material
respects to the description thereof contained in the Prospectus and the General Disclosure Package.
(xii) Except as disclosed in the General Disclosure Package and the Prospectus, there are no
contracts, agreements or understandings between the Company and any person that would give rise to
a valid claim against the Company or any Underwriter for a brokerage commission, finder’s fee or
other like payment in connection with this offering.
-4-
(xiii) Other than the Amended and Restated Investor Rights Agreement, which is described in
the Prospectus under the caption “Certain Relationships and Related Party Transactions —
Registration Rights Agreement” and which have been waived, there are no contracts, agreements or
understandings between the Company and any person granting such person the right to require the
Company to file a registration statement under the Act with respect to any securities of the
Company owned or to be owned by such person or to require the Company to include such securities in
the securities registered pursuant to a Registration Statement or in any securities being
registered pursuant to any other registration statement filed by the Company under the Act.
(xiv) The stockholders of the Company have no preemptive rights with respect to the Offered
Securities which have not been waived in connection with the offering of the Offered Securities.
(xv) The Offered Securities have been approved for listing subject to notice of issuance on
The Nasdaq Global Market.
(xvi) No consent, approval, authorization, or order of, or filing with, any governmental
agency or body or any court is required to be obtained or made by the Company for the consummation
of the transactions contemplated by this Agreement in connection with the sale of the Offered
Securities, except such as have been obtained and made under the Act and such as may be required
under state securities laws.
(xvii) The execution, delivery and performance of this Agreement, and the consummation of the
transactions herein contemplated will not result in a breach or violation of any of the terms and
provisions of, or constitute a default under (A) any statute, any rule, regulation or order of any
governmental agency or body or any court, domestic or foreign, having jurisdiction over the Company
or any subsidiary of the Company or any of their properties, (B) any agreement or instrument to
which the Company or any such subsidiary is a party or by which the Company or any such subsidiary
is bound or to which any of the properties of the Company or any such subsidiary is subject,
except, in the case of each of (A) and (B), as would not be reasonably expected individually or in
the aggregate to result in a Material Adverse Effect, or (C) the charter or by-laws of the Company
or any such subsidiary, and the Company has full power and authority to authorize, issue and sell
the Offered Securities as contemplated by this Agreement.
(xviii) This Agreement has been duly authorized, executed and delivered by the Company.
(xix) Except as disclosed in the General Disclosure Package, the Company and its subsidiaries
have good and marketable title to all real properties and all other properties and assets owned by
them, in each case free from liens, encumbrances and defects that would materially affect the value
thereof or materially interfere with the use made or to be made thereof by them; and except as
disclosed in the General Disclosure Package, the Company and its subsidiaries hold any leased real
or personal property under valid and enforceable leases with no exceptions that would materially
interfere with the use made or to be made thereof by them.
(xx) The Company and its subsidiaries possess adequate certificates, authorities or permits
issued by appropriate governmental agencies or bodies necessary to conduct the business now
operated by them and have not received any notice of proceedings relating to the revocation or
modification of any such certificate, authority or permit that, if determined adversely to the
Company or any of its subsidiaries, would reasonably be expected individually or in the aggregate
to have a Material Adverse Effect.
-5-
(xxi) No labor dispute with the employees of the Company or any subsidiary exists or, to the
knowledge of the Company, is imminent that would reasonably be expected individually or in the
aggregate to result in a Material Adverse Effect.
(xxii) The Company and its subsidiaries own, possess or can acquire on reasonable terms,
adequate trademarks, trade names and other rights to inventions, know-how, patents, copyrights,
confidential information and other intellectual property (collectively, “intellectual property
rights”) necessary to conduct the business now operated by them, or presently employed by them,
except where the failure to possess such intellectual property rights would not result in a
Material Adverse Effect and have not received any notice of infringement of or conflict with
asserted rights of others with respect to any intellectual property rights that, if determined
adversely to the Company or any of its subsidiaries, would individually or in the aggregate have a
Material Adverse Effect.
(xxiii) Except as disclosed in the General Disclosure Package and the Prospectus, neither the
Company nor any of its subsidiaries is in violation of any statute, any rule, regulation, decision
or order of any governmental agency or body or any court, domestic or foreign, relating to the use,
disposal or release of hazardous or toxic substances or relating to the protection or restoration
of the environment or human exposure to hazardous or toxic substances (collectively, “environmental
laws”), owns or operates any real property contaminated with any substance that is subject to any
environmental laws, is liable for any off-site disposal or contamination pursuant to any
environmental laws, or is subject to any claim relating to any environmental laws, which violation,
contamination, liability or claim would individually or in the aggregate have Material Adverse
Effect; and the Company is not aware of any pending investigation which reasonably would be
expected to lead to such a claim.
(xxiv) Except as disclosed in the General Disclosure Package and the Prospectus, there are no
pending actions, suits or proceedings against or affecting the Company, any of its subsidiaries or
any of their respective properties that, if determined adversely to the Company or any of its
subsidiaries, would individually or in the aggregate have a Material Adverse Effect, or would
materially and adversely affect the ability of the Company to perform its obligations under this
Agreement, or which are otherwise material in the context of the sale of the Offered Securities;
and no such actions, suits or proceedings are threatened or, to the Company’s knowledge,
contemplated.
(xxv) Except as disclosed in the General Disclosure Package and the Prospectus, each of the
Company and its subsidiaries maintains a system of internal accounting controls sufficient to
provide reasonable assurance that (i) transactions are executed in accordance with management’s
general or specific authorizations; (ii) transactions are recorded as necessary to permit
preparation of financial statements in conformity with generally accepted accounting principles and
to maintain accountability for assets; (iii) access to assets is permitted only in accordance with
management’s general or specific authorization and (iv) the recorded accountability for assets is
compared with the existing assets at reasonable intervals and appropriate action is taken with
respect thereto.
(xxvi) Since the date of the latest audited financial statements included in the Prospectus,
there has been no change in the Company’s internal control over financial reporting that has
materially affected, or is reasonably likely to materially affect, the Company’s internal control
over financial reporting.
(xxvii) The Company maintains disclosure controls and procedures (as such term is defined in
Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that comply
with the requirements of the Exchange Act; such disclosure controls and procedures have been
designed to ensure that information required to be disclosed by the Company and its subsidiaries is
accumulated and communicated to the Company’s management, including the Company’s principal
executive officer and principal financial officer by others within those entities; such disclosure
controls and procedures are effective.
-6-
(xxviii) The financial statements included in each Registration Statement and the Prospectus
present fairly the financial position of the Company and its consolidated subsidiaries as of the
dates shown and their results of operations and cash flows for the periods shown, and, except as
otherwise disclosed in the Prospectus, such financial statements have been prepared in conformity
with the generally accepted accounting principles in the United States applied on a consistent
basis and the schedules included in each Registration Statement present fairly the information
required to be stated therein.
(xxix) From and after the date of the initial filing, the Company will be in compliance, in
all material respects, with the applicable provisions of the Xxxxxxxx-Xxxxx Act of 2002 and the
applicable rules and regulations thereunder upon the applicability of such provisions, rules or
regulations, as the case may be, to the Company.
(xxx) Except as disclosed in the General Disclosure Package and the Prospectus, since the date
of the latest audited financial statements included in the Prospectus there has been no material
adverse change, nor any development or event involving a prospective material adverse change, in
the condition (financial or other), business, properties or results of operations of the Company
and its subsidiaries taken as a whole, and, except as disclosed in or contemplated by the
Prospectus, there has been no dividend or distribution of any kind declared, paid or made by the
Company on any class of its capital stock.
(xxxi) No relationship, direct or indirect, exists between or among the Company, on the one
hand, and the directors, officers, shareholders, customers or suppliers of the Company, on the
other hand, which is required to be described in the Registration Statement and the Prospectus and
which is not so described. There are no outstanding loans, advances or guarantees of indebtedness
by the Company to or for the benefit of any of the officers or directors of the Company or any of
their respective family members, except as disclosed in the Registration Statement and the
Prospectus. All transactions by the Company with office holders or control persons of the Company
have been duly approved by the board of directors of the Company, or duly appointed committees or
officers thereof, if and to the extent required under U.S. and Israeli law, as applicable.
(xxxii) The Company and its subsidiaries have not, nor, to the knowledge of the Company, has
any director, officer, agent, employee or other person associated with or acting on behalf of the
Company or its subsidiaries, (A) taken any action, directly or indirectly, that would result in a
violation by such persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules
and regulations thereunder (the “FCPA”) or (B) used any of the funds of the Company or its
subsidiaries with an unlawful purpose or in an unlawful manner for any contribution, gift,
entertainment or other expense relating to political activity or as a means to permit the operation
of the Company or any of its subsidiaries or to obtain any concession in contravention of any
applicable law, made any direct or indirect payment to any foreign or domestic government official
(or “Foreign Official”, as such term is defined in the FCPA) or employee in contravention of any
applicable law from any of the funds of the Company or its subsidiaries, or made any bribe, rebate,
payoff, influence payment, kickback or other unlawful payment in contravention of any applicable
law and (C) to the knowledge of the Company, its affiliates have conducted their businesses in
compliance with the FCPA and have instituted and maintain policies and procedures designed to
ensure, and which are reasonably expected to continue to ensure, continued compliance therewith.
(xxxiii) The operations of the Company and its subsidiaries are and have been conducted at all
times in compliance in all material respects with applicable financial recordkeeping and reporting
requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money
laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or
similar rules, regulations or guidelines, issued, administered or enforced by any governmental
agency (collectively, the “Money Laundering Laws”) and no action, suit or proceeding by or before
any court or governmental agency, authority or body or any arbitrator involving the Company or
any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the
knowledge of the Company, threatened.
-7-
(xxxiv) Neither the Company, nor any of its subsidiaries, or to the knowledge of the Company,
any director, officer, agent, employee or affiliate of the Company or its subsidiaries is currently
subject to any U. S. sanctions administered by the Office of Foreign Assets Control of the U. S.
Treasury Department (“OFAC”); and the Company will not directly or indirectly use the proceeds of
the offering, or lend, contribute or otherwise make available such proceeds to any subsidiary,
joint venture partner or other person or entity, for the purposes of financing the activities of
any person subject to any U.S. sanctions administered by the OFAC.
(xxxv) The Company and its subsidiaries are in compliance in all material respects with all
conditions and requirements stipulated by the instruments of approval granted to it with respect to
the “Approved Enterprise” status of any of the Company’s facilities as well as with respect to the
other grants and tax benefits received by the Company as set forth in the Prospectus and by Israeli
laws and regulations relating to such “Approved Enterprise” status and the aforementioned other tax
benefits received by the Company. The Company has not received any notice of any proceeding or
investigation relating to revocation or modification of any “Approved Enterprise” status granted
with respect to any of the Company’s facilities.
(xxxvi) The Company is not and, after giving effect to the offering and sale of the Offered
Securities and the application of the proceeds thereof as described in the General Disclosure
Package and the Prospectus, will not be an “investment company” as defined in the Investment
Company Act of 1940.
(b) The Selling Stockholder represents and warrants to, and agrees with, the several
Underwriters that:
(i) Neither the Selling Stockholder nor any person acting on behalf of the Selling Stockholder
(other than, if applicable, the Company and the Underwriters) has used or referred to any “free
writing prospectus” (as defined in Rule 405), relating to the Offered Securities except as set
forth on Schedule 1 hereto.
(ii) The Selling Stockholder has, and immediately prior to any Delivery Date on which the
Selling Stockholder is selling shares of the Offered Securities, the Selling Stockholder will have,
good and valid title to, or a valid “security entitlement” within the meaning of Section 8-501 of
the New York Uniform Commercial Code (the “UCC”) in respect of, the shares of the Offered
Securities to be sold by the Selling Stockholder hereunder on such Delivery Date, free and clear of
all liens, encumbrances, equities or claims, except for any liens, encumbrances, equities or claims
arising under the Custody Agreement (as defined below), the Powers of Attorney (as defined below)
and this Agreement.
(iii) Upon payment for the Offered Securities to be sold by such Selling Stockholder, delivery
of such Offered Securities, as directed by the Underwriters, to Cede & Co. (“Cede”) or such other
nominee as may be designated by The Depository Trust Company (“DTC”), registration of such Offered
Securities in the name of Cede or such other nominee and the crediting of such Offered Securities
on the books of DTC to securities accounts of the Underwriters (assuming that neither DTC nor any
such Underwriter has notice of any adverse claim (within the meaning of Section 8-105 of the UCC)
to such Offered Securities), (i) under Section 8-501 of the UCC, the Underwriters will acquire a
valid security entitlement in respect of such Offered Securities and (ii) no action based on any
“adverse claim”, within the meaning of Section 8-102 of the UCC, to such Offered Securities may be
successfully asserted against any of the Underwriters with respect to such security entitlement.
For purposes of this representation, such Selling Stockholder may assume that when such payment,
delivery and crediting occur, (A) such Shares will have been registered in the name of Cede or
another nominee designated by DTC, in each case on the Company’s share registry in accordance with
its certificate of incorporation, bylaws and applicable law, (B) DTC will be registered as
a “clearing corporation” within the meaning of Section 8-102 of the UCC and (C) appropriate
entries to the accounts of the several Underwriters on the records of DTC will have been made pursuant to the UCC.
-8-
(iv) The Selling Stockholder is familiar with the Registration Statement, the Prospectus and
the General Disclosure Package (as amended or supplemented) and has no knowledge of any material
fact, condition or information not disclosed (i) in the Registration Statement, as of the Effective
Date, (ii) in the Prospectus, as of its date and on the applicable date of its delivery or (iii) in
the General Disclosure Package, as of the Applicable Time, that, in each case, could reasonably be
expected to have a Material Adverse Effect.
(v) The Selling Stockholder has placed in custody under a custody agreement (the “Custody
Agreement”) with Mellon Investor Services LLC, as custodian (the “Custodian”), for delivery under this
Agreement, certificates in negotiable form (with signature guaranteed by a participant in the
Securities Transfer Agents Medallion Program, the New York Stock Exchange Medallion Signature
Program or the Stock Exchange Medallion Program) representing the shares of the Offered Securities
to be sold by the Selling Stockholder hereunder.
(vi) The Selling Stockholder has duly and irrevocably executed and delivered a power of
attorney (the “Power of Attorney”) appointing Xxxxxxx X. Xxxxxxx, Xxxxxx X. Xxxx and Xxxx
Xxxxxxxxxxx as attorneys-in-fact (the “Attorneys-in-Fact”), with full power of substitution, and
with full authority (exercisable by any one or more of them) to execute and deliver this Agreement
on such Selling Stockholder’s behalf and to take such other action as may be necessary or desirable
to carry out the provisions hereof on behalf of the Selling Stockholder.
(vii) The Selling Stockholder has full right, power and authority, corporate or otherwise, to
enter into this Agreement, the Custody Agreement and the Power of Attorney.
(viii) Except as disclosed in the General Disclosure Package and the Prospectus, there are no
contracts, agreements or understandings between the Selling Stockholder and any person that would
give rise to a valid claim against the Selling Stockholder or any Underwriter for a brokerage
commission, finder’s fee or other like payment in connection with this offering.
(ix) This Agreement has been duly authorized, executed and delivered by or on behalf of
Selling Stockholder.
(x) The Power of Attorney and the Custody Agreement have been duly and validly authorized,
executed and delivered by or on behalf of the Selling Stockholder and constitute valid and legally
binding obligations of the Selling Stockholder enforceable against the Selling Stockholder in
accordance with their terms, subject to (i) the effects of bankruptcy, insolvency, fraudulent
conveyance, reorganization, moratorium and other similar laws relating to or affecting creditors’
rights generally, (ii) general equitable principles (whether considered in a proceeding in equity
or at law) and (iii) an implied covenant of good faith and fair dealing.
(xi) The execution, delivery and performance of this Agreement, the Custody Agreement and the
Power of Attorney by the Selling Stockholder and the consummation by the Selling Stockholder of the
transactions contemplated hereby and thereby do not and will not (i) conflict with or result in a
breach or violation of any of the terms or provisions of, or constitute a default under, any
indenture, mortgage, deed of trust, loan agreement, license or other agreement or instrument to
which the Selling Stockholder is a party or by which the Selling Stockholder is bound or to which
any of the property or assets of the Selling Stockholder is subject, (ii) result in any violation of the provisions of the charter
or by-laws (or similar organizational documents) of such Selling Stockholder or (iii) result in any
violation of any statute or any order, rule or regulation of any court or governmental agency or
body having jurisdiction over the Selling Stockholder or the property or
assets of the Selling Stockholder, except in the case of clauses (i) and (iii) for such
conflicts, breaches, violations or defaults as would not reasonably be expected to materially
adversely affect such Selling Stockholder’s ability to perform its obligations hereunder and under
the Custody Agreement and the Power of Attorney.
-9-
(xii) No consent, approval, authorization or order of, or filing or registration with, any
court or governmental agency or body having jurisdiction over the Selling Stockholder or the
property or assets of the Selling Stockholder is required for the execution, delivery and
performance of this Agreement, the Custody Agreement or the Power of Attorney by the Selling
Stockholder and the consummation by the Selling Stockholder of the transactions contemplated hereby
and thereby, except for the registration of the Offered Securities under the Act and such consents,
approvals, authorizations, registrations or qualifications as have been obtained or as may be
required under the Exchange Act, by the NASD and under applicable state securities laws in
connection with the purchase and sale of the Offered Securities by the Underwriters.
(xiii) Selling Stockholder is not prompted in the sale of any of the Offered Securities by any
information concerning the Company or its subsidiaries, which is not set forth in the Prospectus or
which will not be set forth in the General Disclosure Package.
(xiv) The Selling Stockholder has not taken and will not take, directly or indirectly, any
action that is designed to or that has constituted or that would reasonably be expected to cause or
result in the stabilization or manipulation of the price of any security of the Company to
facilitate the sale or resale of the shares of the Stock.
3. Purchase, Sale and Delivery of Offered Securities. On the basis of the representations,
warranties and agreements herein contained, but subject to the terms and conditions herein set
forth, the Company and the Selling Stockholder agree, severally and not jointly, to sell to each
Underwriter, and each Underwriter agrees, severally and not jointly, to purchase from the Company
and the Selling Stockholder, at a purchase price of $[•] per share, the number of Firm
Securities set forth below the caption “Company” or “Selling Stockholder”, as the case may be, and
opposite the name of such Underwriter in Schedule A hereto.
The Company and the Selling Stockholder will deliver the Firm Securities to the
Representatives for the accounts of the Underwriters against payment of the purchase price in
Federal (same day) funds by wire transfer to an account at a bank acceptable to the Representatives
drawn to the order of [•] in the case of [•] shares of Firm Securities and [•] in
the case of [•] shares of Firm Securities, at the office of [•], at [•] A.M., New
York time, on [•], or at such other time not later than seven full business days thereafter
as the Representatives and the Company determine, such time being herein referred to as the “First
Closing Date”. For purposes of Rule 15c6-1 under the Securities Exchange Act of 1934, the First
Closing Date (if later than the otherwise applicable settlement date) shall be the settlement date
for payment of funds and delivery of securities for all the Offered Securities sold pursuant to the
offering. The certificates for the Firm Securities so to be delivered will be in definitive form,
in such denominations and registered in such names as the Representatives the Representatives
request and will be made available for checking and packaging at the office of [•] at least
24 hours prior to the First Closing Date.
In addition, upon written notice from the Representatives given to the Company and the Selling
Stockholder from time to time not more than 30 days subsequent to the date of the Prospectus, the
Underwriters may purchase all or less than all of the Optional Securities at the purchase price per
Security to be paid for the Firm Securities. The Company and the Selling Stockholder agree,
severally and not jointly, to sell to the Underwriters the respective numbers of Optional
Securities obtained by multiplying the number of shares specified in such notice by a fraction the
numerator of which is [•] in the case of the Company and [•] in the case of the Selling
Stockholder and the denominator of which is the total number of Optional Securities (subject to
adjustment by the Representatives to eliminate fractions). Such Optional Securities shall be
purchased from the Company and the Selling Stockholder for the account of each
Underwriter in the same proportion as the number of Firm Securities set forth opposite such
Underwriter’s name bears to the total number of Firm Securities (subject to adjustment by the
Representatives to eliminate fractions) and may be purchased by the Underwriters only for the
purpose of covering over-allotments made in connection with the sale of the Firm Securities. No
Optional Securities shall be sold or delivered unless the Firm Securities previously have been, or
simultaneously are, sold and delivered. The
-10-
right to purchase the Optional Securities or any
portion thereof may be exercised from time to time and to the extent not previously exercised may
be surrendered and terminated at any time upon notice by the Representatives to the Company and the
Selling Stockholder.
Each time for the delivery of and payment for the Optional Securities, being herein referred
to as an “Optional Closing Date”, which may be the First Closing Date (the First Closing Date and
each Optional Closing Date, if any, being sometimes referred to as a “Closing Date”), shall be
determined by the Representatives but shall be not later than five full business days after written
notice of election to purchase Optional Securities is given. The Company and the Selling
Stockholder will deliver the Optional Securities being purchased on each Optional Closing Date to
the Representatives for the accounts of the several Underwriters against payment of the purchase
price therefor in Federal (same day) funds by official bank check or checks or wire transfer to an
account at a bank acceptable to the Representatives the Representatives drawn to the order of
[•], at the office of [•]. The certificates for the Optional Securities being
purchased on each Optional Closing Date will be in definitive form, in such denominations and
registered in such names as the Representatives requests upon reasonable notice prior to such
Optional Closing Date and will be made available for checking and packaging at the office of
[•] at a reasonable time in advance of such Optional Closing Date.
4. Offering by Underwriters. It is understood that the several Underwriters propose to offer
the Offered Securities for sale to the public as set forth in the Prospectus.
5. Certain Agreements of the Company and the Selling Stockholder. The Company agrees with the
several Underwriters and the Selling Stockholder that:
(a) Company has filed or will file each Statutory Prospectus pursuant to and in accordance
with Rule 424(b)(1) (or, if applicable and consented to by the Representatives, subparagraph (4))
not later than the second business day following the earlier of the date it is first used or the
date of this Agreement.
(b) If the Effective Time of the Initial Registration Statement is prior to the execution and
delivery of this Agreement, the Company will file the Prospectus with the Commission pursuant to
and in accordance with subparagraph (1) (or, if applicable and if consented to by the
Representatives (which consent shall not be unreasonably withheld or delayed), subparagraph (4)) of
Rule 424(b) not later than the earlier of (A) the second business day following the execution and
delivery of this Agreement or (B) the fifteenth business day after the Effective Date of the
Initial Registration Statement.
The Company will advise the Representatives promptly of any such filing pursuant to Rule
424(b). If the Effective Time of the Initial Registration Statement is prior to the execution and
delivery of this Agreement and an additional registration statement is necessary to register a
portion of the Offered Securities under the Act but the Effective Time thereof has not occurred as
of such execution and delivery, the Company will file the additional registration statement or, if
filed, will file a post-effective amendment thereto with the Commission pursuant to and in
accordance with Rule 462(b) on or prior to 10:00 P.M., New York time, on the date of this Agreement
or, if earlier, on or prior to the time the Prospectus is printed and distributed to any
Underwriter, or will make such filing at such later date as shall have been consented to by the
Representatives (which consent shall not be unreasonably withheld or delayed).
(c) The Company will advise the Representatives promptly of any proposal to amend or
supplement the initial or any additional registration statement as filed or the related prospectus
or the Initial Registration Statement, the Additional Registration Statement (if any) or the
Prospectus and will not effect such amendment or supplementation without Credit Suisse’s and Xxxxxx Brothers’s consent; and
the Company will also advise the Representatives promptly of the effectiveness of each Registration
Statement (if its Effective Time is subsequent to the execution and delivery of this Agreement) and
of any amendment or supplementation of a Registration Statement or the Prospectus and of the
institution by the Commission
-11-
of any stop order proceedings in respect of a Registration Statement
and will use commercially reasonable efforts to prevent the issuance of any such stop order and to
obtain as soon as possible its lifting, if issued.
(d) If, at any time when a prospectus relating to the Offered Securities is required to be
delivered under the Act in connection with sales by any Underwriter or dealer, any event occurs as
a result of which the Prospectus as then amended or supplemented would include an untrue statement
of a material fact or omit to state any material fact necessary to make the statements therein, in
the light of the circumstances under which they were made, not misleading, or if it is necessary at
any time to amend the Prospectus to comply with the Act, the Company will promptly notify the
Representatives of such event and will promptly prepare and file with the Commission, at its own
expense, an amendment or supplement which will correct such statement or omission or an amendment
which will effect such compliance. Neither Credit Suisse’s nor Xxxxxx Brothers’s consent to, nor
the Underwriters’ delivery of, any such amendment or supplement shall constitute a waiver of any of
the conditions set forth in Section 7. If any time following issuance of an Issuer Free Writing
Prospectus, there occurred or occurs, an event or development as a result of which such Issuer Free
Writing Prospectus conflicted or would conflict with the information contained in the Registration
Statement related to the Offered Securities or included or would include an untrue statement of a
material fact or omitted or would omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances prevailing at that subsequent time, not
misleading, the Company will promptly notify the Representatives and will promptly amend or
supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such
conflict, untrue statement or omission.
(e) As soon as practicable, but not later than the Availability Date (as defined below), the
Company will make generally available to its securityholders an earnings statement covering a
period of at least 12 months beginning after the Effective Date of the Initial Registration
Statement (or, if later, the Effective Date of the Additional Registration Statement) which will
satisfy the provisions of Section 11(a) of the Act. For the purpose of the preceding sentence,
“Availability Date” means the 45th day after the end of the fourth fiscal quarter
following the fiscal quarter that includes such Effective Date, except that, if such fourth fiscal
quarter is the last quarter of the Company’s fiscal year, “Availability Date” means the
90th day after the end of such fourth fiscal quarter.
(f) The Company will furnish to the Representatives copies of each Registration Statement
(which will be signed and will include all exhibits), each related preliminary prospectus, and, so
long as a prospectus relating to the Offered Securities is required to be delivered under the Act
in connection with sales by any Underwriter or dealer, the Prospectus and all amendments and
supplements to such documents, in each case in such quantities as the Representatives reasonably
request. The Prospectus shall be so furnished as soon as reasonably practicable, but in no event
later than 10:00 A.M., New York time, on the second business day following the later of the
execution and delivery of this Agreement or the Effective Time of the Initial Registration
Statement. All other such documents shall be so furnished as soon as available. The Company will pay the expenses of printing and distributing to
the Underwriters all such documents.
(g) The Company shall cooperate with the Representatives and counsel to qualify the Offered
Securities for sale under the laws of such jurisdictions as the Representatives designate and will
continue such qualifications in effect so long as required for the distribution of the Offered
Securities; provided, however, that the Company shall not be obligated to qualify or register as a
foreign corporation or as a dealer in securities or take any action that would subject it to
general service of process in any such jurisdiction or subject itself to taxation in respect of
doing business in any jurisdiction in which it is not otherwise so subject.
(h) For the period specified below (the “Lock-Up Period”), the Company will not offer, sell,
contract to sell, pledge or otherwise dispose of, directly or indirectly, or file or cause to be
filed with the Commission a registration statement under the Act (other than a Registration
Statement on Form S-8 or its successor) relating to, any additional shares of its Securities or
securities convertible into or
-12-
exchangeable or exercisable for any shares of its Securities, or
publicly disclose the intention to make any such offer, sale, pledge, disposition or filing,
without the prior written consent of the Representatives except issuances of Securities pursuant to
the conversion or exchange of convertible or exchangeable securities or the exercise of warrants or
options, in each case outstanding on the date hereof, grants of employee stock awards pursuant to
the terms of a plan in effect on the date hereof or issuances of Securities pursuant to the
exercise of such awards. The initial Lock-Up Period will commence on the date hereof and will
continue and include the date 180 days after the date hereof or such earlier date that the
Representatives consent to in writing; provided, however, that if (1) during the last 17 days of
the initial Lock-Up Period, the Company releases earnings results or material news or a material
event relating to the Company occurs or (2) prior to the expiration of the initial Lock-Up period,
the Company announces that it will release earnings results during the 16-day period beginning on
the last day of the initial Lock-Up Period, then in each case the Lock-Up Period will be extended
until the expiration of the 18-day period beginning on the date of release of the earnings results
or the announcement of the material news or material event, or, in the event that no announcement
is made by the Company with respect to such material news or material event, the occurrence of such
material news or material event, as applicable, unless the Representatives waive, in writing, such
extension. The Company will provide the Representatives with notice of any announcement described
in clause (2) of the preceding sentence that gives rise to an extension of the Lock-up Period.
(i) The Company agrees with the several Underwriters that the Company will pay all expenses
incident to the performance of the obligations of the Company, as the case may be, under this
Agreement, for any filing fees and other expenses (including fees and disbursements of counsel) in
connection with qualification of the Offered Securities for sale under the laws of Canada and such
jurisdictions as the Representatives designate and the preparation, printing and distribution of
Blue Sky memoranda relating thereto, for the preparation, printing and distribution of one or more
versions of the Prospectus for distribution in Canada (often in the form of a Canadian “wrapper”)
(including related fees and expenses of Canadian counsel to the underwriters), for the filing fee
and other expenses (including fees and other expenses of counsel) incident to the review by the
National Association of Securities Dealers, Inc. of the Offered Securities, for any fees and/or
expenses incurred by the Company in connection with the listing of the Offered Securities on the
NASDAQ Global Market, for any travel expenses of the Company’s officers and employees and any other
expenses of the Company in connection with attending or hosting meetings with prospective
purchasers of the Offered Securities, including the cost of any aircraft chartered in connection
with attending or hosting such meetings and for expenses incurred in distributing preliminary
prospectuses and the Prospectus (including any amendments and supplements thereto) to the
Underwriters and for expenses incurred for preparing, printing and distributing any Issuer Free
Writing Prospectuses to investors or prospective investors.
(j) The Selling Stockholder agrees during the Lock-Up Period not to offer, sell, contract to
sell, pledge or otherwise dispose of, directly or indirectly, any additional shares of the
Securities of the Company or securities convertible into or exchangeable or exercisable for any
shares of Securities, enter into a transaction which would have the same effect, or enter into any
swap, hedge or other arrangement that transfers, in whole or in part, any of the economic
consequences of ownership of the Securities, whether any such aforementioned transaction is to be
settled by delivery of the Securities or such other securities, in cash or otherwise, make any
demand for or exercise any right or cause to be filed a registration statement, including any
amendments thereto, with respect to the registration of any shares of Securities convertible into
or exercisable or exchangeable for Securities or any other securities of the Company or publicly
disclose the intention to make any such offer, sale, pledge or disposition, or enter into any such
transaction, swap, hedge or other arrangement, without, in each case, the prior written consent of
the Representatives. The initial Lock-Up Period will commence on the date hereof and will continue
and include the date 180 days after the date hereof or such earlier date that the Representatives
consent to in writing; provided, however, that if (1) during the last 17 days of the initial
Lock-Up Period, the Company releases earnings results or material news or a material event relating to the Company occurs
or (2) prior to the expiration of the initial Lock-up Period, the Company announces that it will
release earnings results during the 16-day period beginning on the last day of the initial Lock-Up
Period, then in each case the Lock-Up Period will be extended until the expiration of the 18-day
period beginning on the date of release
-13-
of the earnings results or the announcement of or, in the
event that no announcement is made by the Company with respect to such material news or material
event, the occurrence of such material news or material event, as applicable, unless the
Representatives waive, in writing, such extension.
6. Free Writing Prospectuses. The Company represents and agrees that, unless it obtains the
prior consent of the Representatives, and each Underwriter represents and agrees that, unless it
obtains the prior consent of the Company and the Representatives, it has not made and will not make
any offer relating to the Offered Securities that would constitute an Issuer Free Writing
Prospectus or that would otherwise constitute a “free writing prospectus,” as defined in Rule 405,
required to be filed with the Commission. Any such free writing prospectus consented to by the
Company and the Representatives is hereinafter referred to as a “Permitted Free Writing
Prospectus.” The Company represents that it has treated and agrees that it will treat each
Permitted Free Writing Prospectus as an “issuer free writing prospectus,” as defined in Rule 433
and has complied and will comply with the requirements of Rules 164 and 433 applicable to any
Permitted Free Writing Prospectus, including timely Commission filing where required, legending and
record keeping. The Company represents that it has satisfied and agrees that it will satisfy the
conditions in Rule 433 to avoid a requirement to file with the Commission any electronic road show.
7. Conditions of the Obligations of the Underwriters. The obligations of the several
Underwriters to purchase and pay for the Firm Securities on the First Closing Date and the Optional
Securities to be purchased on each Optional Closing Date will be subject to the accuracy of the
representations and warranties on the part of the Company and the Selling Stockholder herein, to
the accuracy of the statements of Company officers made pursuant to the provisions hereof, to the
performance by the Company and the Selling Stockholder of their obligations hereunder and to the
following additional conditions precedent:
(a) The Representatives shall have received a letter of KPMG LLP, dated the date of delivery
thereof (which, if the Effective Time of the Initial Registration Statement is prior to the
execution and delivery of this Agreement, shall be on or prior to the date of this Agreement or, if
the Effective Time of the Initial Registration Statement is subsequent to the execution and
delivery of this Agreement, shall be prior to the filing of the amendment or post-effective
amendment to the registration statement to be filed shortly prior to such Effective Time), in form
and substance satisfactory to the Representatives containing statements and information of the type
ordinarily included in accountants’ “comfort letters” to underwriters with respect to the financial
statements and certain financial information contained in the Registration Statement, the Statutory
Prospectus and the Prospectus; provided that (x) the letter delivered on the Closing Date shall use
a “cut-off date” not earlier than the date hereof and (y) the letter delivered on the Optional
Closing Date shall use a “cut-off date” not earlier than the applicable Option Closing Date, as the
case may be.
(b) If the Effective Time of the Initial Registration Statement is not prior to the execution
and delivery of this Agreement, such Effective Time shall have occurred not later than 10:00 P.M.,
New York time, on the date of this Agreement or such later date as shall have been consented to by
the Representatives. If the Effective Time of the Additional Registration Statement (if any) is
not prior to the execution and delivery of this Agreement, such Effective Time shall have occurred
not later than 10:00 P.M., New York time, on the date of this Agreement or, if earlier, the time
the Prospectus is printed and distributed to any Underwriter, or shall have occurred at such later
date as shall have been consented to by the Representatives. If the Effective Time of the Initial
Registration Statement is prior to the execution and delivery of this Agreement, the Prospectus
shall have been filed with the Commission in accordance with the Rules and Regulations and Section
5(b) of this Agreement. Prior to such Closing Date, no stop order suspending the effectiveness of
a Registration Statement shall have been issued and no proceedings for that
purpose shall have been instituted or, to the knowledge of the Selling Stockholder, the
Company or the Representatives, shall be contemplated by the Commission.
(c) Subsequent to the execution and delivery of this Agreement, there shall not have occurred
(i) any change, or any development or event involving a prospective change, in the condition
-14-
(financial or other), business, properties or results of operations of the Company and its
subsidiaries taken as one enterprise which, in the judgment of the Representatives, is material and
adverse and makes it impractical or inadvisable to proceed with completion of the public offering
or the sale of and payment for the Offered Securities; (ii) any downgrading in the rating of any
debt securities of the Company by any “nationally recognized statistical rating organization” (as
defined for the purposes of Rule 436(g) under the Act), or any public announcement that any such
organization has under surveillance or review its rating of any debt securities of the Company
(other than announcement with positive implications of the possible upgrading, and no implication
of a possible downgrading, of such rating); (iii) any change in United States, Israel or
international financial, political or economic conditions or currency exchange rates or exchange
controls as would, in the judgment of the Representatives, be likely to prejudice materially the
success of the proposed issue, sale or distribution of the Offered Securities, whether in the
primary market or in respect of dealings in the secondary market; (iv) any material suspension or
material limitation of trading in securities generally on the New York Stock Exchange, or any
setting of minimum prices for trading on such exchange; (v) any banking moratorium declared by U.S.
Federal or New York authorities; (vi) any major disruption of settlements of securities or
clearance services in the United States or (vi) any attack on, outbreak or escalation of
hostilities or act of terrorism involving the United States or Israel, any declaration of war by
Congress or any other national or international calamity or emergency if, in the judgment of the
Representatives, the effect of any such attack, outbreak, escalation, act, declaration, calamity or
emergency makes it impractical or inadvisable to proceed with completion of the public offering or
the sale of and payment for the Offered Securities.
(d) The Representatives shall have received an opinion and certain negative assurances, dated
such Closing Date, of Xxxxxx Godward Kronish LLP, counsel for the Company, in the form and
substance substantially set forth in Attachment 1 hereto.
(e) The Representatives shall have received an opinion, dated such Closing Date, of Gross,
Kleinhendler, Hodak, Halevy, Xxxxxxxxx & Co., Israeli counsel for the Company, to the effect that:
(i) Veraz Networks Ltd., a company organized under the laws of the State of Israel (the
“Israeli Subsidiary”) has been duly incorporated and is validly existing as a corporation under the
laws of the State of Israel, with requisite corporate power and authority to conduct its business
as described in the Prospectus; to the knowledge of such counsel, no proceeding has been instituted
by the Registrar of Companies in Israel for the dissolution of the Israeli Subsidiary;
(ii) the outstanding ordinary shares of Israeli Subsidiary have been duly and validly
authorized, issued and are fully paid, nonassessable and are owned directly or indirectly by the
Company;
(iii) the statements included in the Prospectus under the heading “Risk Factors — Risks
Related to Our Operations in Israel,” insofar as such statements describe Israeli statutes, rules
and regulations, constitute fair summaries thereof;
(iv) to such counsel’s knowledge and other than as set forth in the Prospectus and without
conducting any search of the dockets of any court, administrative or regulatory body: (a) there are
no legal or governmental proceedings pending in or before any Israeli court or Israeli governmental
agency to which the Israeli Subsidiary is a party or of which any property of the Israeli
Subsidiary or any of its respective subsidiaries is the subject which, if determined adversely to
the Israeli Subsidiary, the Company or any of their respective subsidiaries, would individually or
in the aggregate have a Material Adverse Effect on the current or future consolidated financial
position stockholders’ equity or results of operations of the Company and its subsidiaries; and, to such counsel’s
knowledge, (b) no such proceedings are threatened by any Israeli governmental authorities or
threatened by others;
(v) no consent, approval, authorization, order, license, registration or qualification of or
with any Israeli court or governmental agency or body is required for the issue and sale
-15-
of the Shares in accordance with this Agreement or the consummation by the Company of the transactions
contemplated by this Agreement, except such consents, approvals, authorizations, licenses,
registrations or qualifications as have been obtained in connection with the purchase and
distribution of the Securities by the Underwriters or the absence of which would have a Material
Adverse Effect; provided that with respect to the opinion set forth
in this subsection (v), such counsel has assumed, without independent verification, that, no
offering of securities will be made in the State of Israel; and
(vi) the issue and sale of the Shares being delivered at each Closing to be sold by the
Company and execution, delivery and compliance by the Company with all of the provisions of this
Agreement and the consummation of the transactions herein contemplated will not conflict with or
result in a breach or violation of any of the terms or provisions of, or constitute a default under
any of the agreements listed as an exhibit to such counsel’s opinion and to which the Israeli
Subsidiary is a party or by which the Israeli Subsidiary is bound or to which any of the property
or assets of the Israeli Subsidiary is subject, nor will such action result in any violation of (a)
the provisions of the articles of association or other organizational documents of the Israeli
Subsidiary, or (b) any Israeli statute, rule or regulation known to such counsel to be customarily
applicable to transactions of the nature contemplated by this Agreement, of or (c) to such
counsel’s knowledge, any judgment, order or decree of any Israeli court or Israeli governmental
agency or body having jurisdiction over Israeli Subsidiary or any of
its material properties.
In rendering the its opinion in paragraph (e), such counsel may state that its opinion is
limited solely to matters governed by the laws of the State of Israel. Such counsel may rely upon
information made available on-line by the Israeli Registrar of Companies and upon certificates of
the responsible officers of the Company and the Israeli Subsidiary in respect of matters of fact,
provided that (A) such counsel shall state that they believe that both the Underwriters and and
they are justified in relying upon such certificates, and (B) a copy of such certificates are
provided to the Underwriters and counsel to the Underwriters.
(f) The Representatives shall have received an opinion, dated such Closing Date, of Goldfarb,
Levy, Eran, Meiri & Co., Israeli counsel for the Selling Stockholder, to the effect that:
(i) The Selling Stockholder had full right, power and authority to enter into this Agreement
and the Custody Agreement and Power of Attorney and to sell, assign, transfer and deliver the
Offered Securities delivered by the Selling Stockholder on such Closing Date hereunder;
(ii) No consent, approval, authorization or order of, or filing with, any Israeli governmental
agency or body or any Israeli court is required to be obtained or made by the Selling Stockholder
for the consummation of the transactions contemplated by this Agreement in connection with the sale
of the Offered Securities sold by the Selling Stockholder;
(iii) The execution, delivery and performance of this Agreement, the Custody Agreement, the
Power of Attorney and the consummation of the transactions herein and therein contemplated will not
result in a breach or violation of any of the terms and provisions of, or constitute a default
under, any Israeli statute, any rule, regulation or order of any Israeli governmental agency or
body or any Israeli court having jurisdiction over the Selling Stockholder or any of its Israeli
properties or the memorandum or articles of association of the Selling Stockholder or, to the
knowledge of such counsel, any agreement or instrument to which Selling Stockholder is a party or
by which the Selling Stockholder is bound or which any of the properties of the Selling Stockholder
is subject;
(iv) This Agreement, the Custody Agreement and the Power of Attorney have been duly
authorized, executed and delivered by the Selling Stockholder and are binding obligations of
Selling Stockholder; and
(v) The submission by the Selling Stockholder under this Agreement to the jurisdiction of any
court sitting in New York and the designation of New York law to apply to this
-16-
Agreement, is binding upon the Selling Stockholder and, if properly brought to the attention of a court or
administrative body in accordance with the laws of the State of Israel, would be enforceable in any
judicial or administrative proceeding in Israel; subject to the existence of special circumstances
or considerations and subject generally to the discretion of the Israeli court ruling on the
matter; subject to certain time limitations, Israeli courts are empowered to enforce foreign final
non-appealable executory judgments in civil matters, obtained after completion of process before a
court which was, according to the laws of the state of such court, competent to render the
judgment, and such court is in a state that recognizes similar Israeli judgments, provided such
judgments or the enforcement thereof are not contrary to Israeli law, public policy, security or
the sovereignty of the State of Israel; and the enforcement of judgments is conditional upon: (a)
adequate service of process being effected and the defendant having had a reasonable opportunity to
be heard; (b) such judgment having been obtained before a court of competent jurisdiction according
to the rules of private international law prevailing in Israel; (c) such judgment being enforceable
in the jurisdiction which it was given and not being in conflict with another valid judgment in the
same matter between the same parties; (d) such judgment not having been obtained by fraudulent
means; and (e) an action between the same parties in the same matter not pending in any Israeli
court at the time the lawsuit is instituted in the foreign court.;
(g) The Representatives shall have received an opinion, dated such Closing Date, of Xxxxxx
Xxxxx Xxxxxxxx & Xxxxxxx LLP, U.S. counsel for the Selling Stockholder, to the effect that:
(i) Upon payment for the Offered Securities to be sold by such Selling Stockholder, delivery
of such Offered Securities, as directed by the Underwriters, to Cede & Co. (“Cede”) or such other
nominee as may be designated by The Depository Trust Company (“DTC”), registration of such Offered
Securities in the name of Cede or such other nominee and the crediting of such Offered Securities
on the books of DTC to securities accounts of the Underwriters (assuming that neither DTC nor any
such Underwriter has notice of any adverse claim (within the meaning of Section 8-105 of the UCC)
to such Offered Securities), (i) under Section 8-501 of the UCC, the Underwriters will acquire a
valid security entitlement in respect of such Offered Securities and (ii) no action based on any
“adverse claim”, within the meaning of Section 8-102 of the UCC, to such Offered Securities may be
successfully asserted against any of the Underwriters with respect to such security entitlement.
In giving this opinion, counsel to the Selling Stockholder may assume that when such payment,
delivery and crediting occur, (A) such Offered Securities will have been registered in the name of
Cede or another nominee designated by DTC, in each case on the Company’s share registry in
accordance with its certificate of incorporation, bylaws and applicable law, (B) DTC will be
registered as a “clearing corporation” within the meaning of Section 8-102 of the UCC and (C)
appropriate entries to the accounts of the several Underwriters on the records of DTC will have
been made pursuant to the UCC;
(ii) No consent, approval, authorization or order of, or filing with, any U.S. governmental
agency or body or any court is required to be obtained or made by the Selling Stockholder for the
consummation of the transactions contemplated by this Agreement in connection with the sale of the
Offered Securities sold by the Selling Stockholder, except such as have been obtained and made
under the Act and such as may be required under state securities laws;
(iii) The execution, delivery and performance of this Agreement, the Custody Agreement, the
Power of Attorney and the consummation of the transactions herein and therein contemplated will not
result in a breach or violation of any of the terms and provisions of, or constitute a default
under, any U.S. statute, any rule, regulation or order of any governmental agency or body or any
court having jurisdiction over the Selling Stockholder or any of its properties; and
(iv) Assuming that they have been duly authorized, executed and delivered by the Selling
Stockholder, the Custody Agreement and the Power of Attorney and are binding obligations of Selling
Stockholder.
-17-
(h) The Representatives shall have received from Xxxxxx Xxxxxxx Xxxxxxxx & Xxxxxx,
Professional Corporation, counsel for the Underwriters, such opinion or opinions, dated such
Closing Date, with respect to the incorporation of the Company, the validity of the Offered
Securities delivered on such Closing Date, the Registration Statements, the Prospectus and other
related matters as the Representatives may require, and the Selling Stockholder and the Company
shall have furnished to such counsel such documents as they reasonably request for the purpose of
enabling them to pass upon such matters.
(i) The Representatives shall have received a certificate, dated such Closing Date, of the
President or any Vice President and a principal financial or accounting officer of the Company in
which such officers, to the best of their knowledge after reasonable investigation, shall state
that: the representations and warranties of the Company in this Agreement are true and correct; the
Company has complied with all agreements and satisfied all conditions on its part to be performed
or satisfied hereunder at or prior to such Closing Date; no stop order suspending the effectiveness
of any Registration Statement has been issued and no proceedings for that purpose have been
instituted or are contemplated by the Commission; the Additional Registration Statement (if any)
satisfying the requirements of subparagraphs (1) and (3) of Rule 462(b) was filed pursuant to Rule
462(b), including payment of the applicable filing fee in accordance with Rule 111(a) or (b) under
the Act, prior to the time the Prospectus was printed and distributed to any Underwriter; and,
subsequent to the respective dates of the most recent financial statements in the Prospectus, there
has been no material adverse change, nor any development or event involving a prospective material
adverse change, in the condition (financial or other), business, properties or results of
operations of the Company and its subsidiaries taken as a whole except as set forth in the
Prospectus or as described in such certificate.
(j) The Representatives shall have received a letter, dated such Closing Date, of KPMG LLP
which meets the requirements of subsection 7 of this Section, except that the specified date
referred to in such subsection will be a date not more than three days prior to such Closing Date
for the purposes of this subsection.
(k) On or prior to the date of this Agreement, the Representatives shall have received lock-up
letters from each of the executive officers, directors and stockholders of the Company.
(l) To avoid a 28% backup withholding tax the Selling Stockholder will deliver to Credit
Suisse a properly completed and executed United States Treasury Department Form W-8BEN (or other
applicable form or statement specified by Treasury Department regulations in lieu thereof).
The Selling Stockholder and the Company will furnish the Representatives with such conformed copies
of such opinions, certificates, letters and documents as the Representatives reasonably request.
the Representatives may in their sole discretion waive on behalf of the Underwriters compliance
with any conditions to the obligations of the Underwriters hereunder, whether in respect of an
Optional Closing Date or otherwise.
8. Indemnification and Contribution. (a) The Company will indemnify and hold harmless each
Underwriter, its partners, members, directors officers and its affiliates and each person, if any
who controls such Underwriter within the meaning of Section 15 of the Act, against any losses,
claims, damages or liabilities, joint or several, to which such Underwriter may become subject,
under the Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in
respect thereof) arise out of or are based upon any untrue statement or alleged untrue statement of
any material fact contained in any Registration Statement, the Prospectus, or any amendment or
supplement thereto, any related preliminary prospectus or any Issuer Free Writing Prospectus, any
“road show” (as defined in Rule 433) not constituting an Issuer Free Writing Prospectus (the
"Non-Prospectus Road Show”) or any Blue Sky application or other
document prepared or executed by the Company (or based upon any written information furnished
by the Company for use therein) specifically for the purpose of qualifying any or all of the
Offered Securities under the securities laws of any state or other jurisdiction (any such
application, document or information being hereinafter called a “Blue Sky Application”), or arise
out of or are based upon the omission or
-18-
alleged omission to state therein a material fact required
to be stated therein or necessary to make the statements therein not misleading, and will reimburse
each Underwriter for any legal or other expenses reasonably incurred by such Underwriter in
connection with investigating or defending any such loss, claim, damage, liability or action as
such expenses are incurred; provided, however, that the Company will not be liable in any such case
to the extent that any such loss, claim, damage or liability arises out of or is based upon an
untrue statement or alleged untrue statement in or omission or alleged omission from any of such
documents in reliance upon and in conformity with written information furnished to the Company by
any Underwriter through the Representatives specifically for use therein, it being understood and
agreed that the only such information furnished by any Underwriter consists of the information
described as such in subsection (d) below. This indemnification obligation shall be in addition to
any liability which the Company may otherwise have.
(b) Selling Stockholder will indemnify and hold harmless each Underwriter, its partners,
members, directors officers and its affiliates and each person, if any who controls such
Underwriter within the meaning of Section 15 of the Act, against any losses, claims, damages or
liabilities, joint or several, to which such Underwriter may become subject, under the Act or
otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof)
arise out of or are based upon any untrue statement or alleged untrue statement of any material
fact contained in any Registration Statement, the Prospectus, or any amendment or supplement
thereto, any related preliminary prospectus or any Issuer Free Writing Prospectus, any
Non-Prospectus Road Show or any Blue Sky Application, or arise out of or are based upon the
omission or alleged omission to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading, and will reimburse each Underwriter for
any legal or other expenses reasonably incurred by such Underwriter in connection with
investigating or defending any such loss, claim, damage, liability or action as such expenses are
incurred, but only to the extent that such untrue statement or alleged untrue statement in or
omission or alleged omission from any such documents was made in reliance upon and in conformity
with written information relating to the Selling Stockholder and furnished by or on behalf of the
Selling Stockholder specifically for use therein. This indemnification obligation shall be in
addition to any liability which the Selling Stockholder may otherwise have. Without limiting the
full extent of the Company’s agreement to indemnify each Underwriter pursuant to Section 8(a), as
herein provided, the liability of the Selling Stockholder with respect to this Section 8(b) shall
not exceed the aggregate gross proceeds received, but before expenses, from the sale of Securities
by Selling Stockholder.
(c) Insofar as the foregoing indemnity agreement as set forth in Sections 8(a) and 8(b), or
the representations and warranties contained in Section 2 may permit indemnification for
liabilities under the Act of any person who is an Underwriter or partner or controlling person of
an Underwriter within the meaning of Section 15 of the Act and who, at the date of this Agreement
is a director, officer or controlling person of the Company, the Company has been advised that in
the opinion of the Commission such provisions may contravene Federal public policy as expressed in
the Act and may therefore be unenforceable. In the event that a claim for indemnification under
such agreement or such representations and warranties for any such liabilities (except insofar as
such agreement provides for the payment by the Company of expenses incurred or paid by a director,
officer or controlling person in the successful defense of any action, suit or proceeding) is
asserted by such a person, the Company will submit to a court of appropriate jurisdiction for the
question of whether or not indemnification by it for such liabilities is against public policy as
expressed in the Act and therefore unenforceable, and the Company will be governed by the final
adjudication of such issue.
(d) Each Underwriter will severally and not jointly indemnify and hold harmless the Company,
its directors and officers and each person, if any, who controls the Company within the meaning of
Section 15 of the Act, and the Selling Stockholder against any losses, claims, damages or
liabilities to which the Company or the Selling Stockholder may become subject, under the Act or otherwise,
insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of
or are based upon any untrue statement or alleged untrue statement of any material fact contained
in any Registration Statement, the Prospectus, or any amendment or supplement thereto, or any
related preliminary prospectus, or arise out
-19-
of or are based upon the omission or the alleged
omission to state therein a material fact required to be stated therein or necessary to make the
statements therein not misleading, in each case to the extent, but only to the extent, that such
untrue statement or alleged untrue statement or omission or alleged omission was made in reliance
upon and in conformity with written information furnished to the Company by such Underwriter
through the Representatives specifically for use therein, and will reimburse any legal or other
expenses reasonably incurred by the Company and the Selling Stockholder in connection with
investigating or defending any such loss, claim, damage, liability or action as such expenses are
incurred, it being understood and agreed that the only such information furnished by any
Underwriter consists of (i) the following information in the Prospectus furnished on behalf of each
Underwriter: the concession and reallowance figures appearing in the fourth paragraph under the
caption “Underwriting,” (ii) the information contained in the fourth and eleventh paragraphs under
the caption “Underwriting,” (iii) the information contained in the 13th paragraph under
the caption “Underwriting” related to stabilizing transactions, syndicate covering transactions and
penalty bids and (iv) the information in the 15th paragraph under the caption
“Underwriting” related to prospectuses in electronic format and Internet distributions.
(e) Promptly after receipt by an indemnified party under this Section of notice of the
commencement of any action, such indemnified party will, if a claim in respect thereof is to be
made against an indemnifying party under subsection (a), (b) or (d) above, notify the indemnifying
party of the commencement thereof; but the failure to notify the indemnifying party shall not
relieve it from any liability that it may have under subsection (a), (b) or (d) above except to the
extent that it has been materially prejudiced (through the forfeiture of substantive rights or
defenses) by such failure; and provided further that the failure to notify the indemnifying party
shall not relieve it from any liability that it may have to an indemnified party otherwise than
under subsection (a), (b) or (d) above. In case any such action is brought against any indemnified
party and it notifies an indemnifying party of the commencement thereof, the indemnifying party
will be entitled to participate therein and, to the extent that it may wish, jointly with any other
indemnifying party similarly notified, to assume the defense thereof, with counsel satisfactory to
such indemnified party (who shall not, except with the consent of the indemnified party, be counsel
to the indemnifying party), and after notice from the indemnifying party to such indemnified party
of its election so to assume the defense thereof, the indemnifying party will not be liable to such
indemnified party under this Section for any legal or other expenses subsequently incurred by such
indemnified party in connection with the defense thereof other than reasonable costs of
investigation. No indemnifying party shall, without the prior written consent of the indemnified
party, effect any settlement of any pending or threatened action in respect of which any
indemnified party is or could have been a party and indemnity could have been sought hereunder by
such indemnified party unless such (i) settlement includes an unconditional release of such
indemnified party from all liability on any claims that are the subject matter of such action and
(ii) does not include a statement as to, or an admission of, fault, culpability or a failure to act
by or on behalf of an indemnified party.
(f) If the indemnification provided for in this Section is unavailable or insufficient to hold
harmless an indemnified party under subsection (a), (b) or (d) above, then each indemnifying party
shall contribute to the amount paid or payable by such indemnified party as a result of the losses,
claims, damages or liabilities referred to in subsection (a), (b) or (d) above (i) in such
proportion as is appropriate to reflect the relative benefits received by the Company and the
Selling Stockholder on the one hand and the Underwriters on the other from the offering of the
Securities or (ii) if the allocation provided by clause (i) above is not permitted by applicable
law, in such proportion as is appropriate to reflect not only the relative benefits referred to in
clause (i) above but also the relative fault of the Company and the Selling Stockholder on the one
hand and the Underwriters on the other in connection with the statements or omissions which
resulted in such losses, claims, damages or liabilities as well as any other relevant equitable
considerations. The relative benefits received by the Company and the Selling Stockholder on the
one hand and the Underwriters on the other shall be deemed to be in the same proportion as the
total net proceeds from the offering (before deducting expenses) received by the Company and the
Selling Stockholder bear to the total underwriting discounts and commissions received by the Underwriters. The relative fault shall
be determined by reference to, among other things, whether the untrue or alleged untrue statement
of a material fact or the omission or alleged omission to state a material fact relates to
information supplied by the Company, the Selling Stockholder or the Underwriters and the parties’
relative intent, knowledge, access to information
-20-
and opportunity to correct or prevent such untrue
statement or omission. The amount paid by an indemnified party as a result of the losses, claims,
damages or liabilities referred to in the first sentence of this subsection (f) shall be deemed to
include any legal or other expenses reasonably incurred by such indemnified party in connection
with investigating or defending any action or claim which is the subject of this subsection (f).
Notwithstanding the provisions of this subsection (f), no Underwriter shall be required to
contribute any amount in excess of the amount by which the total price at which the Securities
underwritten by it and distributed to the public were offered to the public exceeds the amount of
any damages which such Underwriter has otherwise been required to pay by reason of such untrue or
alleged untrue statement or omission or alleged omission. No person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Act) shall be entitled to
contribution from any person who was not guilty of such fraudulent misrepresentation. The
Underwriters’ obligations in this subsection (f) to contribute are several in proportion to their
respective underwriting obligations and not joint.
(g) The obligations of the Company and the Selling Stockholder under this Section shall be in
addition to any liability which the Company and the Selling Stockholder may otherwise have and
shall extend, upon the same terms and conditions, to each person, if any, who controls any
Underwriter (as hereinafter defined) within the meaning of the Act; and the obligations of the
Underwriters under this Section shall be in addition to any liability which the respective
Underwriters may otherwise have and shall extend, upon the same terms and conditions, to each
director of the Company, to each officer of the Company who has signed a Registration Statement and
to each person, if any, who controls the Company within the meaning of the Act.
9. Default of Underwriters. If any Underwriter or Underwriters default in their obligations
to purchase Offered Securities hereunder on either the First or any Optional Closing Date and the
aggregate number of shares of Offered Securities that such defaulting Underwriter or Underwriters
agreed but failed to purchase does not exceed 10% of the total number of shares of Offered
Securities that the Underwriters are obligated to purchase on such Closing Date, the
Representatives may make arrangements satisfactory to the Company and the Selling Stockholder for
the purchase of such Offered Securities by other persons, including any of the Underwriters, but if
no such arrangements are made by such Closing Date, the non-defaulting Underwriters shall be
obligated severally, in proportion to their respective commitments hereunder, to purchase the
Offered Securities that such defaulting Underwriters agreed but failed to purchase on such Closing
Date. If any Underwriter or Underwriters so default and the aggregate number of shares of Offered
Securities with respect to which such default or defaults occur exceeds 10% of the total number of
shares of Offered Securities that the Underwriters are obligated to purchase on such Closing Date
and arrangements satisfactory to the Representatives, the Company and the Selling Stockholder for
the purchase of such Offered Securities by other persons are not made within 36 hours after such
default, this Agreement will terminate without liability on the part of any non-defaulting
Underwriter, the Company or the Selling Stockholder, except as provided in Section 10 (provided
that if such default occurs with respect to Optional Securities after the First Closing Date, this
Agreement will not terminate as to the Firm Securities or any Optional Securities purchased prior
to such termination). As used in this Agreement, the term “Underwriter” includes any person
substituted for an Underwriter under this Section. Nothing herein will relieve a defaulting
Underwriter from liability for its default.
10. Survival of Certain Representations and Obligations. The respective indemnities,
agreements, representations, warranties and other statements of the Selling Stockholder, of the
Company or its officers and of the several Underwriters set forth in or made pursuant to this
Agreement will remain in full force and effect, regardless of any investigation, or statement as to
the results thereof, made by or on behalf of any Underwriter, the Selling Stockholder, the Company
or any of their respective representatives, officers or directors or any controlling person, and
will survive delivery of and payment for the Offered Securities. If this Agreement is terminated
pursuant to Section 9 or if for any reason the purchase of the Offered Securities by the Underwriters is not consummated, the Company and the Selling
Stockholder shall remain responsible for the expenses to be paid or reimbursed by them pursuant to
Section 5 and the respective obligations of the Company, the Selling Stockholder, and the
Underwriters pursuant to Section 7 shall remain in effect, and if any Offered Securities have been
purchased hereunder the representations and
-21-
warranties in Section 2 and all obligations under
Section 5 shall also remain in effect. If the purchase of the Offered Securities by the
Underwriters is not consummated for any reason other than solely because of the termination of this
Agreement pursuant to Section 9 or the occurrence of any event specified in clause (ii), (iii),
(iv), (v) or (vi) of Section 7(c), the Company and the Selling Stockholder will, jointly and
severally, reimburse the Underwriters for all out-of-pocket expenses (including fees and
disbursements of counsel) reasonably incurred by them in connection with the offering of the
Offered Securities.
11. Notices. All communications hereunder will be in writing and, if sent to the
Underwriters, will be mailed, delivered or telegraphed and confirmed to the Representatives c/o
Credit Suisse Securities (USA) LLC, Eleven Xxxxxxx Xxxxxx, Xxx Xxxx, XX 00000-0000, Attention:
Transactions Advisory Group, with a copy to Xxxxxx Brothers Inc., 000 Xxxxxxx Xxxxxx, Xxx Xxxx, XX
00000, Attention: Syndicate Registration (Fax: 000-000-0000), with further copy, in case of any
notice pursuant to Section 8, to the Director of Litigation, Office of the General Counsel, Xxxxxx
Brothers Inc., 000 Xxx Xxx, 00xx xxxxx, Xxx Xxxx, XX 00000 (Fax: 000-000-0000); or, if sent to the
Company, will be mailed, delivered or telegraphed and confirmed to it at 000 Xxxx Xxxxxx, Xxxxx 00,
Xxx Xxxx, XX 00000 (Fax: 000-000-0000), Attention: Xxxx Xxxxxxx, Chief Executive Officer with a
copy to Cooley Godward Kronish LLP, Five Palo Alto Square, 0000 Xx Xxxxxx Xxxx, Xxxx Xxxx, XX
00000-0000 (Fax: 000-000-0000), Attention: Xxxxx X. Xxxxxx, Xx., or, if sent to the Selling
Stockholder, will be mailed, delivered or telegraphed and confirmed to [•] at [•];
provided, however, that any notice to an Underwriter pursuant to Section 8 will be mailed,
delivered or telegraphed and confirmed to such Underwriter.
12. Successors. This Agreement will inure to the benefit of and be binding upon the parties
hereto and their respective successors and the officers and directors and controlling persons
referred to in Section 8, and no other person will have any right or obligation hereunder.
13. Representation. The Representatives will act for the several Underwriters in connection
with the transactions contemplated by this Agreement, and any action under this Agreement taken by
the Representatives or by the Representatives will be binding upon all the Underwriters.
14. Counterparts. This Agreement may be executed in any number of counterparts, each of which
shall be deemed to be an original, but all such counterparts shall together constitute one and the
same Agreement.
15. Absence of Fiduciary Relationship. The Company and the Selling Stockholder acknowledge
and agree that:
(a) The Representatives have been retained solely to act as underwriters in connection with
the sale of the Offered Securities and that no fiduciary, advisory or agency relationship between
the Company or the Selling Stockholder, on the one hand, and the Representatives, on the other, has
been created in respect of any of the transactions contemplated by this Agreement, irrespective of
whether the Representatives have advised or are advising the Company or the Selling Stockholders on
other matters;
(b) the price of the securities set forth in this Agreement was established by the Company and
the Selling Stockholder following discussions and arms-length negotiations with the Representatives
and the Company and the Selling Stockholder are capable of evaluating and understanding and
understand and accept the terms, risks and conditions of the transactions contemplated by this
Agreement;
(c) the Company and the Selling Stockholder have been advised that the Representatives and
their affiliates are engaged in a broad range of transactions which may involve interests that
differ from those of the Company or the Selling Stockholder and that the Representatives have no
obligation to disclose such interests and transactions to the Company or the Selling Stockholder by
virtue of any fiduciary, advisory or agency relationship; and
-22-
(d) the Company and the Selling Stockholder waive, to the fullest extent permitted by law, any
claims they may have against the Representatives for breach of fiduciary duty or alleged breach of
fiduciary duty and agree that the Representatives shall have no liability (whether direct or
indirect) to the Company or the Selling Stockholder in respect of such a fiduciary duty claim or to
any person asserting a fiduciary duty claim on behalf of or in right of the Company, including
stockholders, employees or creditors of the Company.
16. Research Analyst Independence. The Company acknowledges that the Underwriters’ research
analysts and research departments are required to be independent from their respective investment
banking divisions and are subject to certain regulations and internal policies, and that such
Underwriters’ research analysts may hold views and make statements or investment recommendations
and/or publish reports with respect to the Company and/or the offering that differ from the views
of their respective investment banking divisions. The Company and the Selling Stockholder
acknowledge that each of the Underwriters is a full-service securities firm and as such from time
to time, subject to applicable securities laws, may affect transactions for its own account or the
account of its customers and hold long or short positions in debt or equity securities of the
companies that may be subject to the transactions contemplated by this Agreement.
17. Applicable Law. This Agreement shall be governed by, and construed in accordance with,
the laws of the State of New York, without regard to principles of conflicts of laws.
The Company hereby submits to the non-exclusive jurisdiction of the Federal and state courts
in the Borough of Manhattan in The City of New York in any suit or proceeding arising out of or
relating to this Agreement or the transactions contemplated hereby.
-23-
If the foregoing is in accordance with the Representatives’ understanding of our agreement,
kindly sign and return to the Company one of the counterparts hereof, whereupon it will become a
binding agreement among the Selling Stockholder, the Company and the several Underwriters in
accordance with its terms.
Very truly yours, Veraz Networks, Inc. |
||||
By | ||||
Xxxxxxx X. Xxxxxxx, | ||||
Chief Executive Officer | ||||
ECI Telecom Ltd. |
||||
By | ||||
Xxxxxxx X. Xxxxxxx, | ||||
Attorney-in-Fact | ||||
The foregoing Underwriting Agreement is hereby
confirmed and accepted as of the date first
above written.
confirmed and accepted as of the date first
above written.
Credit Suisse Securities (USA) LLC |
||||
By | ||||
Name | ||||
Title | ||||
Xxxxxx Brothers Inc. |
||||
By | ||||
Name | ||||
Title | ||||
Each acting on behalf of itself and as the
Representative of the Underwriters:
Representative of the Underwriters:
Credit Suisse Securities (USA) LLC
Xxxxxx Brothers Inc.
Xxxxxxxx & Company, Inc.
Xxxxxxx Xxxxx & Associates, Inc.
Xxxxxx Brothers Inc.
Xxxxxxxx & Company, Inc.
Xxxxxxx Xxxxx & Associates, Inc.
-24-
SCHEDULE A
Total Number | ||||||||||||
Name of Firm Securities to be Sold by | of Firm | |||||||||||
Selling | Securities to | |||||||||||
Underwriter | Company | Stockholder | be Purchased | |||||||||
Credit Suisse Securities (USA) LLC |
||||||||||||
Xxxxxx Brothers Inc. |
||||||||||||
Xxxxxxxx & Company, Inc. |
||||||||||||
Xxxxxxx Xxxxx & Associates, Inc. |
SCHEDULE 1
FREE WRITING PROSPECTUSES
-2-